EU/3/18/2041
About
On 31 July 2018, orphan designation (EU/3/18/2041) was granted by the European Commission to Ionis USA Ltd, United Kingdom, for 2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA for the treatment of behavioural variant frontotemporal dementia.
The sponsorship was transferred to Biogen Netherlands B.V., The Netherlands in October 2020.
Key facts
Active substance |
2ʹ-O-(2-methoxyethyl) antisense oligonucleotide targeting microtubule-associated protein tau pre-mRNA
|
Disease / condition |
treatment of behavioural variant frontotemporal dementia
|
Date of first decision |
31/07/2018
|
Outcome |
Positive
|
EU designation number |
EU/3/18/2041
|
Sponsor's contact details
Biogen Netherlands B.V.
Prins Mauritslaan 13-19
1171 LP Badhoevedorp Noord-Holland
Netherlands
E-mail: ukreception@biogen.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.